Cantitate/Preț
Produs

Migraine Management: Handbook of Clinical Neurology, cartea 199

Editat de Jerry W. Swanson, Manjit Matharu
en Limba Engleză Hardback – feb 2024
Migraine Management, Volume 199 covers the effective treatment of migraines, including different subtypes of migraines in different patient populations. The classification and diagnostic criteria of common and uncommon subtypes of migraine is explored in detail, including childhood variants. An in-depth analysis of the pharmacology of acute and prophylactic agents is presented, along with an evidence-based review of pharmacologic management. This includes recently developed CGRP monoclonal antibodies and non-peptide small molecule CGRP antagonists. Advances in neuromodulatory treatments, both noninvasive and implantable are also critically reviewed. Finally, specific treatment-related issues in pregnancy and lactation and childhood as well as the elderly are covered. Issues related to the diagnosis and management of vestibular migraine and the co-morbid disorder of persistent postural-perceptual dizziness are also explored.


  • Summarizes evidence-based best treatment for migraines
  • Differentiates treatment based on patient population, migraine type, and clinical setting
  • Includes pharmacological, biobehavioral, and physical treatments
  • Provides specialized treatments for children, the elderly, and pregnant patients
Citește tot Restrânge

Din seria Handbook of Clinical Neurology

Preț: 119850 lei

Preț vechi: 154335 lei
-22% Nou

Puncte Express: 1798

Preț estimativ în valută:
22973 24930$ 19655£

Carte disponibilă

Livrare economică 14-28 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780128233573
ISBN-10: 0128233575
Pagini: 632
Dimensiuni: 192 x 262 mm
Editura: ELSEVIER SCIENCE
Seria Handbook of Clinical Neurology


Cuprins

Section I. Migraine Management 1. Non-specific analgesics, combination analgesics, and antiemetics 2. The 5-HT1B and 5-HT1D Agonists in Acute Migraine Therapy: Ergotamine, dihydroergotamine, and the triptans 3. 5-HT1F agonists 4. CGRP receptor antagonists (Gepants) 5. Preventive treatment of migraine: Non-specific oral agents 6. OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment 7. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention 8. Nutraceuticals in migraine 9. Interventional treatments 10. Biobehavioral treatments of migraine 11. Physical treatment of migraine 12. Neuromodulation in migraine Section II. Guidelines 13. Evidence-based symptomatic treatment of migraine 14. Evidence-based preventive treatment of migraine Section III. Special Cases/Situations 15. Treatment in the emergency department 16. Special considerations in migraine during pregnancy and lactation 17. Special considerations in management of migraine in the elderly 18. Management of medication overuse headache Section IV. Outcome Measures 19. Outcome Measures for Migraine: Measuring the impact of migraine and results of migraine treatment Section V. Diagnosis and Treatment of Other Migraine Subtypes 20. Menstrually associated migraine 21. Hemiplegic migraine 22. Migraine with brainstem aura 23. Retinal migraine 24. Vestibular migraine and persistent postural perceptual dizziness 25. Status migrainosus 26. Persistent aura, visual snow, and other visual symptoms 27. Migrainous infarction 28. Migraine in children and adolescents: Assessment and diagnosis 29. Management of migraine in children and adolescents Section VI. Comorbidities of Migraine 30. Psychiatric comorbidities of migraine 31. Relationship of migraine and other forms of chronic pain 32. Comorbidities of migraine: Sleep disorders 33. The evolving concept of multimorbidity and migraine Section VII. Future Directions 34. Healthcare disparities faced by patients with migraine and potential mitigation strategies 35. Emerging and future directions of migraine research and treatment